Aurinia Pharmaceuticals Inc

AUPHNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
16.54 USD
↘ 0.21 (1.25%)AT CLOSE (11:59 AM EDT)
16.61
↗ 0.07 (0.45%)
POST MARKET (AS OF 07:33 PM EDT)
Post Market
AS OF 07:33 PM EDT
16.61
↗ 0.07 (0.45%)
🔴Market: CLOSED

Aurinia Pharmaceuticals Inc (AUPH) is currently trading at $16.54. The stock presents a bullish profile across the board: both technical indicators and our fundamental models signal a "Strong Buy" and "Strong Buy" respectively. Notable factors include a robust Altman Z-Score, a strong Piotroski F-Score of 7/9, exceptional Return on Equity (51.1%) and a bullish Golden Cross on the moving averages. Valuation metrics place AUPH at a fair price relative to peers.

Technical & fundamental data as of Aug 26, 2026.

Open?$16.60
High?$16.65
Low?$16.34
Prev. Close?$16.75
Volume?778.0K
Avg. Volume?1.1M
VWAP?$16.51
Rel. Volume?0.69x
Bid / Ask
Bid?$16.16 × 600
Ask?$16.65 × 100
Spread?$0.49
Midpoint?$16.41
Valuation & Ratios
Market Cap?2.2B
Shares Out?133.1M
Float?103.0M
Float %?79.2%
P/E Ratio?7.01
P/B Ratio?3.58
EPS?$2.36
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
128
Market Cap
2.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.auriniapharma.com
Listed
2009-10-21
Address
#140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookStrong Buy
Strong SellNeutralStrong Buy
F-Score?
88
Z-Score?
100
Momentum?
90
Short Sent.?
54
Piotroski F-Score?7/9Strong
Altman Z-Score?8.06Safe
Confidence?68%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.34%Elevated
Short Interest?9.6M
Days to Cover?8.0
Free Float103.0M
Avg Daily Volume1.2M
Settlement Date2026-08-14
Financial Health
Current Ratio?5.42Strong
Quick Ratio?4.97Strong
Cash Ratio?1.80Strong
Debt/Equity?0.10Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
Peers
100
S&P
97
7.0CHEAP▾
P/B?
Peers
100
S&P
48
3.58FAIR▾
P/S?
Peers
100
S&P
17
7.06HIGH▾
P/FCF?
Peers
100
S&P
81
12.6CHEAP▾
EV/EBITDA?
Peers
100
S&P
60
13.3FAIR▾
EV/Sales?
Peers
100
S&P
22
6.68HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
91
51.1%STRONG▾
ROA?
Peers
50
S&P
97
39.7%STRONG▾
Cash Flow & Enterprise
FCF?$175.1M
Enterprise Value?$2.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist